Production (Stage)
ARS Pharmaceuticals, Inc.
SPRY
$14.98
$0.463.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 68.51% | 114.71% | 20.32% | 15.94% | -17.23% |
| Total Depreciation and Amortization | 443.75% | 8.22% | -17.33% | 1.64% | 1,500.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 182.90% | 204.99% | -35.76% | -40.67% | -56.26% |
| Change in Net Operating Assets | -101.00% | 75.42% | 77.97% | 59.88% | 32.72% |
| Cash from Operations | 61.75% | 122.86% | 26.46% | 20.12% | -17.47% |
| Capital Expenditure | -778.46% | -221.71% | 56.63% | 80.74% | 82.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -526.89% | -21.30% | 119.36% | 37.17% | 114.30% |
| Cash from Investing | -532.25% | -21.70% | 119.14% | 37.42% | 114.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -40.34% | -56.28% | -38.85% | -20.80% | 209.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,148.13% | 949.41% | -98.35% | -98.20% | -96.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.33% | 85.56% | -189.94% | -210.70% | -189.35% |